The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2003

Filed:

Aug. 15, 2001
Applicant:
Inventors:

Thomas J. Stegmann, Petersberg, DE;

Vitaliy A. Kordyum, Kiev, UA;

Iryna Yu. Slavchenko, Kiev, UA;

Svitlana I. Chernykh, Kiev, UA;

Oleksandr F. Vozianov, Kiev, UA;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12P 1/509 ; C12P 1/518 ; C12P 2/102 ; C12P 3/900 ; C12N 7/01 ;
U.S. Cl.
CPC ...
C12P 1/509 ; C12P 1/518 ; C12P 2/102 ; C12P 3/900 ; C12N 7/01 ;
Abstract

The gene of human acidic fibroblast growth factor 155 (haFGF 155) has been obtained by chemical synthesis. The nucleotide sequence of haFGF 155 gene has been deduced on the basis of haFGF 155 amino acid sequence as described in the literature. The amino acid sequence of the synthesized haFGF 155 does not differ from those described in the literature. The nucleotide sequence of haFGF gene differs from those described previously. For chemical synthesis of haFGF 155 gene, codons were used which are the ones most often used by in highly expressed proteins. A plasmid with haPGF 155 (phaFGF 155) gene was obtained and was used to transform . Production of haFGF 154 protein was achieved by cultivation of the producer strain under conditions which slow down the lytic development of lambda phage. The haFGF 154 protein accumulated in culture medium in a soluble condition as a result of the producer strain cells lysis by the lambda phage. The haFGF 154 protein constituted 20% of the soluble protein accumulated in the culture medium and its biological activity was demonstrated by its ability to generate new vessels (angiogenesis). The initiator methionine residue at position 1 of the FGF 155 protein was completely removed during protein synthesis resulting in an FGF 154 amino acid product. The use of the phage-dependent method to produce other forms of the haFGF protein is also disclosed.


Find Patent Forward Citations

Loading…